Skip to main content
Equibles
NWBO logo

NWBO · Northwest Biotherapeutics Inc

Track NWBO — free

Use NWBO with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.17 0.00 (-0.99%) At close · Aug 21
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Because of recurring operating losses and operating cash flow deficits, there is substantial doubt about the Company’s ability to continue as a going concern for at least one year from the date of this filing. The consolidated financial statements have been prepared assuming that the Company will continue as a going concern, however, they do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets, or the amounts and classification of liabilities that may result from the outcome of this uncertainty.”
View the 10-Q filed Aug 14, 2026
Market Cap
$289.96M
Shares
1.71B

NWBO metrics

58 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.17
Market cap
$289.96M

Price action

19 metrics
Price change (1W)
-11.7%
Price change (30D)
-5.8%
Price change (3M)
-26.3%
Price change (6M)
-29.3%
Price change (YTD)
-26.3%
Price change (1Y)
-32.2%
Trailing year
Price change (5Y)
-85.3%
52-week high
$0.32
52-week low
$0.15
Change from 52-week high
-47.0%
Change from 52-week low
+13.1%
Annualized volatility
71.2%
Beta
0.7
RSI (14D)
42.9
Price vs SMA 50
-5.3%
Price vs SMA 200
-23.3%
Avg volume (3M)
2.98M
Relative volume
1.1
Average dollar volume
$548,626

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
1.71B

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
133.4×
reciprocal yield 0.7%
P / book
—
FCF yield
-17.2%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-13.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
350.8×
reciprocal yield 0.3%
EV / revenue historical average (5Y)
426.3×
reciprocal yield 0.2%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
-2,316.1%
Trailing 12 months
Net margin
-1,736.4%
Gross profit (TTM)
—
Operating profit (TTM)
−$50.33M
Net income (TTM)
−$37.73M
Trailing 12 months
Diluted EPS (TTM)
$-0.03
FCF margin
-2,290.3%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.27

Growth

11 metrics
Revenue growth YoY
+516.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$2.17M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+14.2%
Year over year · more shares
Revenue CAGR (3Y)
-6.4%
Revenue CAGR (5Y)
+1.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-49.7%
Debt / equity
—
Current ratio
0.0
EBITDA (TTM)
−$47.60M
Free cash flow (TTM)
−$49.77M
Quick ratio
0.0
Interest coverage
-5.3
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$595,000
Total assets
$75.94M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$48.34M
Capital expenditures (TTM)
$1.43M
R&D (TTM)
$23.57M
SG&A (TTM)
—
Stock compensation (TTM)
$758,000
R&D / revenue
1,084.5%
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
8
13F filer change QoQ
0
Institutional ownership
0.1%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1072379 CUSIP 66737P600 13F (30d) 3 filings 3 filers Visit website